Briefs: Panacea Biotec and Shukra Pharmaceuticals

Panacea Biotec receives acceptance from CMSS for supply of bOPV

Indian pharmaceutical market grows at 7.3% yoy in September 2025: Ind-Ra

Positive volume growth was observed in key therapies such as respiratory (13.2% yoy), anti-neoplastics (12.1% yoy) and cardiac (4.8% yoy) during September 2025

DMMA warns regulatory burden threatening Gujarat’s pharma MSMEs

The association called for an end to the constant issuance of regulatory circulars that make operations unpredictable and capital-intensive.

Piramal Pharma Solutions boosts formulation development at Morpeth site with Korsch XM-12

FDA prohibits Sun Pharma's Halol Plant from exporting drugs to US

Sun Pharma's Halol plant gets OAI classification from US FDA inspection

Alcon India launches Unity VCS/CS for vitreoretinal and cataract surgery

Breakthrough UNITY 4D Phaco delivers up to 2X faster nucleus removal and 41% less energy into the eye

India preparing to become hub for medical technology: Pharmaceuticals Secretary

Government policies and competitive industry driving India’s MedTech sector for sustained double-digit growth

GST rejig may impact competitiveness of medical devices: AiMeD

AiMeD noted that proposed GST changes—to either 5% or 18%—both present significant risks requiring carefully nuanced consideration

Piramal Pharma Solutions opens dedicated OSD production capabilities at Sellersville, Pennsylvania site

The suite represents a multi-million-dollar investment in equipment upgrades and enhancements to improve the site's capabilities

Marksans Pharma reports Q1 FY26 gross profit 8.9% higher at Rs. 358.2 Cr

EBITDA stood at Rs. 100.1 crore with a margin of 16.1 per cent